Last reviewed · How we verify
Indermil (ENBUCRILATE)
Indermil (generic name: ENBUCRILATE) is a enbucrilate drug. It is currently in Phase 3 development.
Indermil works by forming a strong adhesive bond between the skin and the wound.
Indermil (Enbucrilate) is a small molecule enbucrilate drug used for its adhesive properties in wound closure and skin closure. It works by forming a strong bond between the skin and the wound, promoting healing and reducing the risk of infection. The commercial status of Indermil is not publicly available, and it is not clear if it is patented or available as a generic product. Indermil is used to treat skin wounds and closures, but its exact target and mechanism of action are not well-documented. As a result, key safety considerations and pharmacokinetic properties are not well-established.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | ENBUCRILATE |
|---|---|
| Drug class | enbucrilate |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 3 |
Mechanism of action
Imagine a strong glue that helps hold your skin together while it heals. Indermil is like that glue, but it's a special medicine that helps your skin close up and heal faster. It's not something that gets absorbed into your body, but rather stays on the surface to do its job.
Approved indications
Common side effects
Key clinical trials
- Efficacy of Using Knotless Barbed Suture vs N-Butyl Cyanoacrylate Glue Tissue Adhesive for Closure of Intraoral Surgical Incisions (NA)
- Prevention of Variceal Rebleeding by EUS-guided vs Conventional Endoscopic Therapy in Hepatocellular Carcinoma Patients (NA)
- Middle Meningeal Artery Embolization for the Treatment of Subdural Hematomas With TRUFILL® n-BCA (NA)
- Cyanoacrylate Versus Omentum for Staple-Line Reinforcement in Sleeve Gastrectomy (NA)
- Study On Histoacryl Used For Embolization Of Middle Meningeal Artery (MMA) In Chronic Subdural Hematoma (CSDH) (HARMONY)
- Comparing Tissue Adhesives in Port Site Closure (PHASE3)
- Healing Efficacy of Isobutyl Cyanoacrylate High Viscous Solution in Treatment of Traumatic Ulcer in Children (NA)
- Pancreatic Parenchymal Injection of N-butyl-2-cyanoacrylate (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Indermil CI brief — competitive landscape report
- Indermil updates RSS · CI watch RSS
Frequently asked questions about Indermil
What is Indermil?
How does Indermil work?
What is the generic name of Indermil?
What drug class is Indermil in?
What development phase is Indermil in?
Related
- Drug class: All enbucrilate drugs
- Therapeutic area: All drugs in Dermatology
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing